top of page

476 EDTA Chelation Therapy References, Page 1 of 2


 

1-100

  1. Ahrens FA and Aronson AL: A comparative study of the toxic effects of calcium and chromium chelates of ethylenediaminetetraacetate in the dog. Toxic Appl Pharmac 18:10, 1971.

  2. Ahrens FA and Aronson AL: Toxicity of calcium ethylenediaminetetraacetate in dogs. Fed Proc Fedn Am Soc Exp Biol 27:1401, 1968.

  3. Adams WJ and McGee CT: Chelation therapy: a survey of treatment outcomes and selected socio-medical factors. J Adv Med 5(3):189, 1992.

  4. Agerty HA: Lead poisoning in children. Medical Clinics of North America. (36):1587, 1952.

  5. Ahrens FA and Aronson AL: Comparative study of the toxic effects of calcium chelates of ethylenediaminetetraacetate in the dog. Tox Appl Pharmocol (18)1:10 1971.

  6. Alfthan G, Pikkarainen J, Huttunen JK, Puska P: Association between cardiovascular death and myocardial infarction and serum selenium in a matched- pair longitudinal study. Lancet 2(8291):175, 1982.

  7. Allen AC: The Kidney Grune and Stratton, N.Y., p. 329, 1962.

  8. AItmann J, Wakim KG and Winkelmann RK: Effects of edathamil disodium on the kidney. J Invest Dermatol (38): 215, 1962.

  9. Angle CR and McIntire MS: Lead poisoning during pregnancy. Fetal tolerance of calcium disodium edetate . Am J Dis Child 108:436, 1964.

  10. Ames BN: Dietary carcinogens and anticarcinogens. Science 221:1256, 1983.

  11. Aronov DM: First experience with the treatment of atherosclerosis patients with calcinosis of the arteries with trilon-B (disodium salt of EDTA). (Russ, Moscow) Klin Med 41:19, 1963.

  12. Aronson AL and Ahrens FA: The mechanism of renal transport and excretion of ethylenediaminetetraacetate with interspecies comparison. Toxic Appl Pharmac 18:1, 1971.

  13. Aronson AL and Hammond PB: Effect of two chelating agents on the distribution and excretion of lead. J Pharmacol Exp Ther 146:241-251, 1964.

  14. Aronson AL, Hammond PB and Strafuss AC: Studies with calcium ethylenediaminetetraacetate in calves; toxicity and use in bovine lead poisoning. Toxicol Appl Pharmacol 12:337-349, 1968.

  15. Atherosclerosis and auto oxidation of cholesterol, editorial. Lancet ii:964, 1980.

  16. Batchelor TM, McCall M and Mosher RM: Potassium dieresis induced by edathamil disodium. JAMA 187:305, 1964.

  17. Bates GW, Billups C and Saltman P: The kinetics and mechanism of iron (III) exchange between chelates and transferrin. II. The presentation and removal with ethylenediaminetetraacetate. J Biol Chem 242:2816, 1967.

  18. Batuman V, Landy E, Maesaka JK, Wedeen RP: Contribution of lead to hypertension with renal impairment .N EngI J Med 309(1):17, 1983.

  19. Batuman V, Maesaka JK, Haddad B, et al: The role of lead in gout nephropathy. N.E.J.M. (304)9:520, 1981.

  20. Bauer RO, Rullo FR, Spooner C, et al: Acute and subacute toxicity of ethylene diamine tetraacetic acid (EDTA) salts. Federation Proc (11): 321, 1952.

  21. Bechtel JT, White JE and Estes EH Jr: The electrocardiographic effects of hypocalcemia induced in normal subjects with edathamil disodium. Circulation 13:837, 1956.

  22. Belknap EL: EDTA in the treatrment of lead poisoning. Indust Med & Surg (21):305,1952.

  23. Berkman N, Michaeli Y, Or R and Eldor A: EDTA dependent pseudothrombocytopenia: a clinical study of 18 patients and a review of the literature. Am J Hematol 36:195, 1991.

  24. Bessman SP, Ried H and Rubin M: Treatment of lead encephalopathy with calcium disodium versenate. Ann Med Soc DC 21:312, 1952.

  25. Bhat RK, et a!: Trace elements in hair and environmental exposure. Sci Total Environ 22(2):169, 1982.

  26. Birk RE and Rupe CE: The treatment of systemic sclerosis with disodium EDTA, pyridoxine and reserpine. Henry Ford Hosp Med Bull 14:109, 1966.

  27. Birk RE and Rupe CE: Systemic sclerosis. Fourteen cases treated with chelation (disodium EDTA) and/or pyridoxine, with comments on the possible role of altered tryptophan metabolism in pathogenesis. Henry Ford Hosp Med Bull 10:523, 1962.

  28. Bjorksten J: The cross-linkage theory of aging as a predictive indicator. Rejuvenation 8:59, 1980.

  29. Bjorksten J: Possibilities and limitations of chelation as a means for life extension. Rejuvenation 8:67, 1980.

  30. Blake DR, Hall ND, Bacon PA, Dieppe PA, Halliwell B, Gutteridge JM: The importance of iron in rheumatoid disease. Lancet :1142, 1981.

  31. Blake DR, Hall ND, Bacon PA, Dieppe PA, Halliwell B, Gutteridge JMC: Effect of a specific iron chelating agent on animal models of inflammation. Ann Rheum Dis 42:89, 1983.

  32. Bland JS: The utility of hair analysis: A reevaluation. J Holistic Medicine 5(1):16, 1983.

  33. Blumer W, Reich T: Leaded gasoline – cause of cancer. Environmental International 3:465, 1980.

  34. Blumer W and Cranton EM: Ninety percent reduction in cancer mortality after chelation therapy with EDTA. J Adv Med 2:183, 1989.

  35. Bolick LE and Blankenhorn DH: A quantitative study of coronary arterial calcification. Am J Path 39:511, 1961.

  36. Boyle AJ, Jasper JJ, McCormick H, et al: Studies in human and induced atherosclerosis employing – (EDTA). Bull Swiss Acad Med Sci 13:408, 1957.

  37. Boyle M, Wegria R, Cathcart RT, et al: Effects of intravenous injections of nicotine on the circulation. Am Heart J (34): 65, 1947.

  38. Boyle AJ, Clarke NE, Mosher RE, McCann DS: Chelation therapy in circulatory and sclerosing diseases. Fed Proc 20(3) (Part II) (suppl 10):243-257, 1961.

  39. Boyle AS, Mosher LE, McCann DS: Some in vivo effects of chelation-I: Rheumatoid arthritis. J Chronic Dis 16:325, 1963.

  40. Brachet P and Klein C: Cell response to CAMP during aggregation phase of Dictyostelium discoideum. Comparison of the inhibitory effects of progesterone and the stimulatory action of EDTA and ionophore A23187. Differention (8)1:1, 1977.

  41. Brecher A: Bye-Bye Bypass: The Truth About Chelation Therapy. Troup, Texas, Health Savers Press, 1989.

  42. Brien TG and Fay J: [51Cr] EDTA biological half life as an index of renal function. J Nuc Med. (13) 5:339, 1972.

  43. Brecher A: Bye-Bye Bypass: The Truth About Chelation Therapy. Troup, Texas, Health Savers Press, 1989.

  44. Brucknerova O, Tulacek J and Krojzl O: Chelates in the treatment of obliterating arteriopathies. Vnitrni Lek 14:841, 1968.

  45. Brucknerova 0 and Malinovska V: First clinical experience with combined treatment with chelation III and glucagon in ischemic disease of the lower extremities, Cas Lek Cas 119:814,1980.

  46. Brucknerova 0, Tulacek J: Chelates in the treatment of occlusive atherosclerosis. (Czech, Praha) Vnitr Lek 18:729, 1972.

  47. BurckhardIt P, Boillat AM, Reudi B, et al: Effect of parathyroid hormone immunoheterogeneity. Schweiz Med Wochenschr (105) 50:1692, 1975.

  48. Butler AM: Use of calcium ethylenediaminetetraacetate in treating heavy-metal poisoning. Arch Indust Hyg Occupat Med 7:136, 1952.

  49. Butterfield JD, McGraw CP: Free radical pathology. Stroke 9(5):443, 1978.

  50. Calcium disodium edetate and disodium edetate. Drugs for human use; drug efficacy study implementation. Department of Health, Education, and Welfare. Food and Drug Administration. Federal Registrar 35 F.R. 437, 1970.

  51. Casdorph HR: Chelation therapy: a reappraisal. N Z Med J 66, 1983.

  52. Casdorph HR: EDTA chelation therapy, efficacy in arteriosclerotic heart disease. J Holistic Medicine 3(1):53, 1981.

  53. Casdorph HR: EDTA chelation therapy II, efficacy in brain disorders. J Holistic Medicine 3(2):101, 1981.

  54. Casdorph HR, Farr CH: EDTA chelation therapy Ill: Treatment of peripheral arterial occlusion, an alternative to amputation. J Holistic Medicine 3(1):3, 1983.

  55. Cashion WR Jr: What about chelation? Texas Medicine 80:6, 1984.

  56. Castellino N and Aloj S: Effects of calcium sodium ethylenediaminetetra-acetate on the kinetics of the distribution and excretion of lead in the rat. Brit J Indust Med 22:172, 1965.

  57. Catsch A: Radioactive metal mobilization. Fed Proc 20 (Suppl 10):206, 1961.

  58. Catsch A and Harmuth-Hoene AE: Pharmacology and therapeutic applications of agents used in heavy metal poisoning. Pharmac Ther. A, (1):1, 1976.

  59. Chaitlow L: Chelation Therapy: The Revolutionary Alternative to Heart Surgery. San Francisco, Thorsons SF, 1991.

  60. Chantler C and Barratt TM: Estimation of glomerular filtration rate from plasma clearance of 51-chromium edetic acid. Arch Dis Child 47:613, 1972.

  61. Chantler C, Garnett ES, Parsons V and Veall N: Glomerular filtration rate measurement in man by the single injection method using 51Cr-EDTA. Clin Sci 37:169, 1969.

  62. Chappell LT and Stahl JP: The correlation between EDTA chelation therapy and improvement in cardiovascular function: a meta-analysis. J Adv Med 6(3):139, 1993.

  63. Chappell LT, Stahl JP and Evans R: EDTA chelation treatment for vascular disease: a meta-analysis using unpublished data. J Adv Med 7(3),131, 1994.

  64. Chappell LT, Janson M, Whitaker J: A challenge to cardiovascular surgeons. J Adv Med (In Press)

  65. Chappell LT: Chelation therapy, smoking and health care costs (Letter). J Adv Med 7:107, 1994.

  66. Chappell LT: EDTA chelation therapy should be more commonly used in the treatment of vascular disease. Alternative Therapies Health Med 1:53, 1995.

  67. Chappell LT, Miranda R, Rubin M, Carter JP and Trowbridge J: Chelation therapy (Letter). Circulation 92:1350, 1995.

  68. Chelation therapy (Diagnostic and therapeutic technology assessment). JAMA 250:672, 1983.

  69. Chelation therapy: a second look. The Harvard Medical School Health Letter, IX:1, 1984.

  70. Chelation Therapy Clinic: Chelation therapy – the treatment of choice for relief from and prevention of, cardiovascular and age-related diseases. Aukland, New Zealand, The Chelation Therapy Clinic, 1987.

  71. Chelation therapy. Resolution: 66 (I-84). AMA House of Delegates. 1984.

  72. Chelation therapy. Report of the Council on Scientific Affairs. Report F (I-84). AMA House of Delegates. 1984.

  73. Chelation therapy – An informal summary. Department of Health & Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland. June 1992.

  74. Chen IW, Park HM, King LR, Bahr GK and Goldsmith RE: Radioimmunoassay of parathyroid hormone: peripheral plasma immunoreactive parathyroid hormone response to ethylenediaminetetraacetate. J Nucl Med 15:763, 1974.

  75. Cheraskin E, Wussow DG, McDonagh EW and Rudolph CJ: Effect of EDTA chelation and supportive multivitamin/trace mineral supplementation with and without physical activity on the heart rate. J InternAcadof Prev Medi 8(6):5, 1984.

  76. Chisolm JJ Jr: Chelation therapy in children with subclinical plumbism. Pediatrics 53:441, 1974.

  77. Chisolm JJ Jr: The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediat 73:1, 1968.

  78. Clarke NE Sr, Clarke NE Jr, Mosher RE: Treatment of occlusive vascular disease with disodium ethylene diamine tetraacetic acid (EDTA). The Amer J of the Med Sci June:732, 1960.

  79. Clarke NE, Clarke CN, and Mosher RE: Treatment of angina pectoris with disodium ethylene diamine tetra-acetic acid. Am J of Med Sci 232:654, 1956.

  80. Clarke NE Sr: Atherosclerosis, occlusive vascular disease and EDTA. Am J Cardiol 6(2):233, 1960.

  81. Clarke NE, Clarke CN, Mosher RE: The “in vivo” dissolution of metastatic calcium: An approach to atherosclerosis. Am J Med Sci 229:142,1955.

  82. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31, 1976.

  83. Cohen SH, Gong JK and Fishler MC: Ethylene diamine tetraacetic acid (EDTA) treatment of internal radioactive contamination. Nucleonics (11)1: 56, 1953.

  84. Cohen S, Weissler AM and Schoenfeld CD: Antagonism of the contractile effect of digitalis by EDTA in the normal human ventricle. Am Heart J 69:502, 1965.

  85. Cook JD, Finch CA, Smith NJ: Evaluation of the iron status of a population. Blood 48(3):449, 1976.

  86. Couric JM: Chelation therapy overdone. FDA Consumer 16:28. 1982.

  87. Cranton EM and Frackelton JP: Negative Danish Study of EDTA chelation biased. Townsend Letter for Doctors July, 604-605, Letter, 1992.

  88. Cranton EM: Critique of the American Medical Association’s published position on hair analysis. J Holistic Medicine 8(1);47, 1986.

  89. Cranton EM, Bland JS, Chatt A, Krakovitz R, Wright JV: Standardization and interpretation of human hair for elemental concentrations. J Holistic Medicine 1982;4:10, 1982.

  90. Cranton EM: Update on hair analysis in clinical medicine. J Holistic Medicine 7(2):120,1986.

  91. Cranton EM and Frackelton JP: The current status of EDTA chelation therapy in the treatment of occlusive arterial disease. Journal of Holistic Medicine 4: 24, 1982.

  92. Cranton EM: Protocol of the American College of Advancement in Medicine for the safe and effective administration of EDTA chelation therapy. J Adv Med 2:269, 1989.

  93. Cranton EM: A textbook on EDTA chelation therapy. J Adv Med 2:1-416, 1989.

  94. Cranton EM and Frackelton JP: Free radical pathology in age associated diseases; treatment with EDTA chelation, nutrition and antioxidants. J Holistic Med 6: 1, 1984.

  95. Cranton EM: Kidney effects of ethylene diamine tetraacetic acid (EDTA): A literature review. J Holistic Medicine 4:152, 1982.

  96. Cranton EM: The current status of EDTA chelation therapy, editorial. J Holistic Med 7(1):3, 1985.

  97. Cranton EM, Brecher A: Bypassing Bypass: The New Technique of Chelation Therapy ed 2 ,Medex Publishers Inc, P.O. Box 44, Trout Dale, VA 24378, 1989.

  98. Craven, PC and Morelli HF: Chelation therapy. West J Med, 122:277, 1975.

  99. Curran CL: Metal chelating agents and hepatic cholesterol synthesis. Proc Soc Exper Biol & Med 88:101, 1955.

  100. Darwish NM and Kratzer FH: Metabolism of ethylenediaminetetraacetic acid (EDTA) by chickens. J Nutr 86:187, 1965.

 

​101-200

  1. David 0, Hoffman SP, Sverd J, Clark J, Voeller K: Lead and hyperactivity, behavioral response to chelation: A pilot study. Am J Psychiatry 133:1155, 1976.

  2. Davis FA, Becker FO, Michael JA and Sorensen E: Effect of intravenous sodium bicarbonate disodium EDTA and hyperventilation on visual and oculomotor signs in multiple sclerosis. J Neurol Neuro-surg Psychiat 33:723, 1970.

  3. Davis PS and Deller DJ: Effect of orally administered chelating agents EDTA, DTPA and fructose on radioiron absorption in man. Aust Ann Med 16:70, 1967.

  4. Davis H and Moe PJ: Favorable response of calcinosis universalis to edathamil disodium. Pediatriacs 24:780, 1959.

  5. Deftos LJ, Goodman AD, Engleman K, et al: Suppression and stimulation of calcitonin secretion in medullary thyroid carcinoma. Metab Clin Med. (20)4: 428, 1971.

  6. Del Maestro RF: An approach to free radicals in medicine and biology. Acta Physiol Scand 492(suppl):153, 1980.

  7. Demopoulos HB: The basis of free radical pathology. Fed Proc 32:1859, 1973.

  8. Demopoulos, HB: Control of free radicals in the biologic systems. Fed Proc 32: 1903, 1973.

  9. Demopoulos HB, Pietronigro DD, Flamm ES, Seligrnan ML: The possible role of free radical reactions in carcinogenesis. Journal of Environmental Pathology and Toxicology 3:273, 1980.

  10. Demopoulos HB, Flamm ES, Pietronigro DD, Seligman ML: The free radical pathology and the microcirculation in the major central nervous system disorders. Acta Physiol Scand 492(suppl):91, 1980.

  11. Demopoulus HB: Molecular oxygen in health and disease. Presented AAMP Tenth Annual Spring Meeting May 21, 1983, Los Angeles, California.

  12. Demopoulos HB, Peitronigro DD, Seligman ML: The development of secondary pathology with free radical reactions as a threshold mechanism. J Am Coll Tox 2(3):173, 1983.

  13. Deucher DP: EDTA chelation therapy: an antioxidant strategy. J Adv Med 1:182, 1988.

  14. Deucher GP: Heay metals, chelation therapy, free radicals and human disease. Angiologie, Octobre 1987.

  15. Diagnostic and therapeutic technology assessment: chelation therapy. JAMA 250:672,1983.

  16. Dix T: Metabolism of polycyclic aromatic hydrocarbon derivatives to ultimate carcinogens during lipid peroxidation. Science 221:77, 1983.

  17. Donald GF, Hunter GA, Roman W and Taylor AEJ: Current concepts of cutaneous porphyria and its treatment with particular reference to the use of sodium calcium-edetate. Brit J Derm 82:70, 1970.

  18. Donsbach KW: Chelation Therapy; Has the Plug Been Pulled on Our Biggest Killer? Huntington Beach, CA, International Institute of Health, 1981.

  19. Doolan PD, Schwartz SL, Hayes JR, Mullen JC, Cummings NB: An evaluation of the nephrotoxicity of ethylene diamine tetraacetate and diethylene trinenine pentaacetate in the rat. Toxicol AppI Pharmocol 10:481, 1967.

  20. Dormandy Tl: Free-radical reaction in biological systerms. Ann R Coll Surg Engl 62:188, 1980.

  21. Dormandy TL: Free-radical oxidation and antioxidants, Lancet i:647, 1978.

  22. Dormandy TL: An approach to free radicals. Lancet 1983; ii:1010, 1983.

  23. Dudley HR, Ritchie A, Schilling A, et al: Pathologic changes associated with the use of sodium ethylene diamine tetraacetate in the treatment of hypercalcemia. NEJM (252): 331, 1955.

  24. EDTA chelation therapy for arteriosclerotic heart disease. Medical Letter 23,1981.

  25. EDTA chelation: a rebuttal. J Adv Med 5:3, 1992.

  26. EDTA chelation therapy for atherosclerotic cardiovascular disease. Medical Letter 36:48 l994.

  27. Eliot RS and Blout SG Jr: Calcium, chelates and digitalis. A clinical study. Am Heart J 62:7, 1961.

  28. Elwood PC, Benjamin IT, Waters WE, Sweetnam PM: Mortality and anemia in women. Lancet :891, 1974.

  29. Emmerson BT: Chronic lead nephropathy. The diagnostic use of calcium EDTA and the association with gout. Australian Ann Med 12: 310, 1963.

  30. Emmerson BT and Thiele BR: Calcium versenate in the diagnosis of chronic lead nephropathy. Med J Aust (1): 243,1960.

  31. Ericson JE, Shirahata H, Patterson CC: Skeletal concentrations of lead in ancient Peruvians. N Engl J Med 300:946, 1979.

  32. Estep HL, Gardner CT Jr, Taylor JP, Minott A and Tucker HStG Jr: Phosphate excretion patterns following intravenous injection of ethylenediaminetetraacetate ((EDTA). J Clin Endocr 25:1385, 1965.

  33. Favre HR and Wing AJ: Simultaneous 51Cr edetic acid, inulin, and endogenous creatinine clearances in 20 patients with renal disease. Brit Med J 1:84, 1968.

  34. Feigen RD, Shannon DC, Reynolds SL, Shapiro LW and Connelly JP: Lead poisoning in children. Clin Pediat 4:38, 1965.

  35. Fine SD: Calcium disodium edetate and disodium edetate. Drugs for human use; Drug efficacy study implementation. Fed Reg (35)8: Jan. 13, 1970.

  36. Fink CW and Baum J: Treatment of calcinosis universalis with chelating agents. Am J Dis Child 105:390, 1963.

  37. Flamm ES, Demopoulos HB, Seligman ML, Poser RG, Ransohoff J: Free radicals in cerebral ischemia. Stroke 9(5):445,1978.

  38. 140 Flynn DM: 5-year controlled trial of chelating agents in treatment of thalassaemia major. Arch Dis Child 48:829, 1973.

  39. Flytlie K and Hancke C: Letter to the editor: EDTA manipulated. J Adv Med 6(1):53, 1993.

  40. Foote CS: Chemistry of singlet oxygen VII. Quenching by beta carotene. J Am Chem Soc 90:6233, 1968.

  41. Foreman H: Pharmacology of some useful chelating agents. In Seven MJ and Johnson LA (eds): Metal-Binding in Medicine. Philadelphia, JB Lippincott, 1960.

  42. Foreman H: The use of chelating agents for excelerating excretion of radioelements. J Am Pharm Assoc (42): 629, 1953.

  43. Foreman H: Toxic side effects of ethylenediaminetetraacetic acid. J Chron Dis (16):319, 1963.

  44. Foreman H: Summary remarks by the chairman. [Proceedings of a conference on biological apects of metal-binding.] Fed Proc 20 (Suppl 10):257, 1961.

  45. Foreman H: Use of chelating agents in treatment of metal poisoning with special emphsis on lead). Fed Proc 20 (Suppl 10):191, 1961.

  46. Foreman H, Finnegan C and Lushbough C: Nephrotoxic hazard from uncontrolled edathamil calcium disodium therapy. JAMA (160): 1042, 1956.

  47. Foreman H, Vier M and Magee M: The metabolism of C14 labeled ethylenediaminetetraacetic acid in the rat. J Biol Chem 203:1045, 1953.

  48. Foreman H, Finnegan C and Lushbaugh CC: Nephrotoxic hazard from uncontrolled edathamil calcium-disodium therapy. JAMA 160:1042, 1956.

  49. Foreman H, Hardy H, Shipman T, et al: Use of calcium ethylenediaminetetraacetate in cases of lead intoxication. Ama Archiv Indust Hyg Occup Med (7): 148, 1953.

  50. Foreman H and Trujillo T: Metabolism of carbon 14 labeled ethylenediaminetetraacetic acid in human beings. J Lab Clin Med (43): 566, 1954.

  51. Forssman O and Nordqvist P: The action in vitro and in vivo of sodium versenate on the phagocytic activity of neutrophile leukocytes. Acta Haemat 31:289, 1964.

  52. Frackelton JP, Cranton EM: Iron and copper supplementation with EDTA chelation therapy. J Holistic Med 8(1):63, 1986.

  53. Frackelton JP: Monitoring renal function during EDTA chelation therapy. J Holistic Med 8(1):33, 1986.

  54. Friedel W, Schulz FH Schroder L: Therapy of atherosclerosis through mucopolysaccarides and EDTA (ethylene diamine tetraacetic acid). (German) Deutsch Gesundh 20:1566, 1965.

  55. Fromke VL, Lee MY and Watson CJ: Porphyrin metabolism during Versenate® therapy in lead poisoning. Intoxication from an unusual source. Ann Intern Med 70:1007, 1969.

  56. Fuleihan FJD, Kurban AK, Abboud RT, Beidas-jubran N and Farah FS: An objective evaluation of the treatment of systemic scleroderma with disodium EDTA, pyridoxine and reserpine. Brit J Derm 80:184, 1968.

  57. Gaby AR: Nutritional factors in cardiovascular disease. J Holistic Medicine 5(2):l07, 1983.

  58. Gerstenblith G, Ouyang P, Achuff S, et al: Nifedipine in unstable angina: A double-blind, randomized trial. NEJM (306)15: 885, 1982.

  59. Ghiringhelli L and Respighi E: The tubular reabsorption of phosphorus during the test of parathyroid stimulation by versenate (test of Kaiser &Ponsold). Atti Acad Med Lombarda 18:191, 1963.

  60. Ghiringhelli L, Marinoni E and Respighi E: Study of the parathyroid function by means of the Kaiser &Ponsold test in a group of thyroidectomized patients. Minerva Med 54:2829, 1963.

  61. Gibbons HL: Edetate disodium calcium, calcium-channel blockers, and heart disease. JAMA 246:1728, 1981.

  62. Godfrey ME: EDTA chelation as a treatment of arteriosclerosis .N Z Med J 93:199, 1990.

  63. Godfrey ME, Frackleton JP and Chappell LT: Chelation therapy for intermittent claudication (Letter). Z Med J 107:495, 1994.

  64. Godfrey ME, Agnihotri R and Strauss A: Chelation and arteriosclerosis. N Z Med J 101(838):21, 1988.

  65. Goetzl EJ: Oxygenation products of arachidonic acid as mediators of hypersensitivity and inflammation. Med Clin North Am 65(4):809, 1981.

  66. Godfrey ME, Frackleton JP and Chappell LT: Chelation therapy for intermittent claudication (Letter). Z Med J 107:495, 1994.

  67. Goodman and Gillman’s Pharmacological Basis of Therapeutics: Heavy Metals and Heavy Metal Antagonists. 6:1615, 1980

  68. Gordon T, Castelli WP, Hjortland MC, et al: High density lipoprotein as a protective factor against coronary heart disease. The Framington Study. Am J Med (62): 707, 1977.

  69. Gordon GB, Vance RB: EDTA chelation therapy for atherosclerosis: History and mechanisms of action. Osteopathic Annals 4:38, 1976.

  70. Gordon GF: Oral chelation with EDTA. J Holistic Medicine 8(1):79, 1986.

  71. Gordon T, Kannel WB, Hjortland MC, McNamara PM: Menopause and coronary heart disease. The Framingham Study. Am Intern Med 89:157, 1978.

  72. Gotto AM Jr: Chelation therapy in 1984. Texas Medicine, 80:36, 1984.

  73. Gould RG: Metals and chelating agents in relation to atherosclerosis. Fed Proc 20 (Suppl 10):252, 1961.

  74. Grier MT and Meyers DG: So much writing, so little science: A review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 27:1504, 1993.

  75. Grumbles LA: Radionuclide studies of cerebral and cardiac arteriography before and after chelation therapy. New Horizons in Holistic Health II (Symposium). Chicago, May 27, 1979.

  76. Guldager B, Jelnes R, Jorgenson SJ, et al: EDTA treatment of intermittent claudication – a double-blind placebo-controlled study. J Intern Med 231:261, 1992.

  77. Gutteridge JMC, Rowley DA, Halliwell B: Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Biochem J 206:605, 1982.

  78. Gutteridge JMC, Rowley DA, Halliwell B and Westermarck T: Increased non-protein-bound iron and decreased protection against superoxide radical damage in cerebrospinal fluid from patients with neuronal ceroid lipofuscinoses. Lancet ii:459,1982.

  79. Halstead BW: The Scientific Basis of EDTA Chelation Therapy. Colton, CA, Golden Quill Publishers, Box 1278, Coltotn, CA 92324,1979.

  80. Hancke C and Flytlie K: Benefits of EDTA chelation therapy in arteriosclerosis: a retrospective study of 470 patients. J Adv Med 6(3):161,1993.

  81. Hancke C and Flytlie K: Manipulation with EDTA. Ugeskr Laeger 154:2213, 1992.

  82. Hansotia P, Peters H, Bennett M and Brown R: Chelation therapy in Wegener’s granulomatosis. Treatment with EDTA. Ann Otol 78:388, 1969.

  83. Hardy HL: Clinical experience with the use of calcium disodium ethylenediaminetetraacetate in the therapy of lead poisoning. Fed Proc 20 (Suppl 10):252, 1961.

  84. Harman D: The aging process. Proc Natl Acad Sci USA 78:7124, 1981.

  85. Harper JW andGordon GF: Reprints of Medical Literature on Chelation Therapy. Los Angeles, American Academy of Medical Preventics, 1975.

  86. Hardy HL: Clinical experience with the use of calcium disodium ethylenediaminetetraacetate in the therapy of lead poisoning. Fed Proc 20 (Suppl 10):252, 1961.

  87. Hatano S, Nishi Y, Usui T: Copper levels in plasma and erythrocytes in healthy Japanese children and adults. Am J Clin Nutr 35:120, 1982.

  88. Haumont S and Vincent J: Action of calcium versenate on lead fixed in vivo in compact bone. Exp Cell Res 18:404, 1959.

  89. Hausmann E: Changes in plasma phosphate concentration on infusion of calcium gluconate or Na2EDTA. Proc Soc Exp Biol Med 134:182, 1970.

  90. Hay DR: Chelation therapy. N Z Med J 101(841):122, 1988.

  91. Hay DR: Chelation therapy. N Z Med J 101(845):246, 1988.

  92. Heath DA, Knapp MS and Walker WHC: Comparison between inulin and 51Cr-labelled edetic acid for the measurement of glomerular filtration-rate. Lancet 2:1110, 1968.

  93. Hegsted DM: Major minerals. Section A. Calcium and phosphorus. In: RS Goodheart and ME Shields (Eds.). Modern Nutrition in Health and Disease. Lea and Febiger, Phila., p. 266, 1974.

  94. Heller J and Vostal J: Renal excretion of calcium-disodium-ethylenediamine-tetraacetic acid – a new tubular secretory mechanism? Experientia 20:99, 1964.

  95. Herd JK and Vaughan JH: Calcinosis universalis complicating dermatomyositis – its treatment with Na2EDTA. Report of two cases in children. Arthritis Rheum 7:259, 1964.

  96. Hess ML, Manson NH, Okabe E: Involvement of free radicals in the pathophysiology of ischemic heart disease. Can J Physiol Pharmacol 60(11):1382, 1982.

  97. Hjortland MC, McNamara PM, Kannel WB: Some atherogenic concomitants of menopause:The Framingham Study. Am J Epidemiol 103:304, 1976.

  98. Holland JF, Danielson E and Sahagian-Edwards A: Use of EDTA in hypercalcemic patients. Proc Soc Exp Biol Med 84:359, 1953.

  99. HoIm LW: The use of calcium disodium salt of Versene in heavy-metal poisoning of livestock. Proc Am Vet Med Assoc (48): 33, 1954.

  100. Hösli P: Therapy of scleroderma with the disodium salt of ethylenediaminetetraacetic acid; a contribution to the toxicology of versenate. Part I. Arzneimittelforschung 10:65, 1960.

​​

bottom of page